Cytokeratin, pan Antibody (AE-1/AE-3)

Pan-Cytokeratin was detected in immersion fixed paraffin-embedded sections of human Breast Tumor using Mouse Anti-Human Cytokeratin, pan Monoclonal Antibody (Catalog # NBP2-29429) at 1:500 at 37 ° Celsius for 4 minutes. Before incubation with the primary antibody, tissue underwent an all-in-one dewaxing and antigen retrieval preprocessing using PreTreatment Module (PT Module) and Dewax and HIER Buffer H (pH 9; Epredia Catalog # TA-999-DHBH). Tissue was stained using the Alexa Fluor™ 555 Goat anti-Mouse IgG Secondary Antibody at 1:100 at 37 ° Celsius for 2 minutes. (Yellow; Lunaphore Catalog # DR555MS) and counterstained with DAPI (blue; Lunaphore Catalog # DR100). Specific staining was localized to the cytoplasm. Protocol available in COMET™ Panel Builder.

Cytokeratin, pan was detected in immersion fixed paraffin-embedded sections of mouse Kidney using Mouse Anti-Human/Mouse Cyokeratin, pan Monoclonal Antibody (Catalog #NBP2-29429) at 1:200 dilution at 37 ° Celsius for 4 minutes. Before incubation with the primary antibody, tissue underwent an all-in-one dewaxing and antigen retrieval preprocessing using PreTreatment Module (PT Module) and Dewax and HIER Buffer H (pH 9; Epredia Catalog # TA-999-DHBH).Tissue was stained using the Alexa Fluor™ 647 Goat anti-Mouse IgG Secondary Antibody at 1:200 at 37 ° Celsius for 2 minutes. (Yellow; Lunaphore Catalog # DR647MS) and counterstained with DAPI (blue; Lunaphore Catalog # DR100). Specific staining was localized to the membrane. Protocol available in COMET™ Panel Builder.

FFPE tissue sections of human metastatic tonsil were probed for Pan Cytokeratin mRNA (ACD RNAScope probe, catalog # 310221; Fast Red chromogen, ACD catalog # 322500). Adjacent tissue section was processes for IHC using mouse monoclonal antibody (Novus catalog # NBP2-29429) at 0.3 ug/mL for 1 hour at room temperature followed by incubation with the anti-mouse IgG VisUCyte HRP Polymer Antibody (Novus Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue).

MCF-7 cells stained with Biotin conjugated version of pan Cytokeratin antibody and SAv-A488. A) SAv-A488 only at a dilution of 1:500, B) pan CK at a dilution of 1:200, C) pan CK at a dilution of 1:400, D) pan CK at a dilution of 1:800. ICC/IF image submitted by a verified customer review.

Analysis using Azide and BSA Free version of NBP2-29429. Human Colon Carcinoma stained with pan Cytokeratin Monoclonal Antibody cocktail (AE-1/AE3).

An intracellular stain was performed on HeLa cells with pan Cytokeratin Antibody (AE1 + AE3) NBP2-33200R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Dylight 550.

Human Pan-Cytokeratins on HeLa Cells. Black: Cells alone; Green: Isotype Control; Red: PE-labeled Pan-Cytokeratin Monoclonal Antibody (AE-1/AE-3)

Human fibroblasts. Blue: fibroblasts. Red: fibroblast + cytokeratin transfection. CyTOF image submitted by a verified customer review.

Flow Cytometry: Cytokeratin, pan Antibody (AE-1/AE-3) [NBP2-29429] - An intracellular stain was performed on HeLa cells with pan Cytokeratin Antibody (AE1 + AE3) NBP2-33200AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647. Image from the AF647 version of this antibody.

Flow Cytometry: Cytokeratin, pan Antibody (AE-1/AE-3) [NBP2-29429] - An intracellular stain was performed on HeLa cells with pan Cytokeratin [AE1 + AE3] Antibody NBP2-33200AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488. Image from the AF488 version of this antibody.

Flow Cytometry: Cytokeratin, pan Antibody (AE-1/AE-3) [NBP2-29429] - An intracellular stain was performed on HeLa cells with pan Cytokeratin Antibody (AE1 + AE3) NBP2-33200PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin. Image from the PE version of this antibody.

• Reactivity: Hu, Mu, Rt, Bv, Ca, Ch, Pm, Rb, Re, Ze
• Applications: WB, Flow, ICC/IF, IHC, COMET, CyTOF-ready, Dual ISH-IHC, mIF, Single-Cell Western
• Clone: AE-1/AE-3
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: 0.2 mg/ml

Cytokeratin, pan Antibody (AE-1/AE-3) Summary

• Description: 200ug/ml of antibody purified from Bioreactor Concentrate by Protein A or G. Prepared in 10 mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0 mg/ml. (NBP2-33200)
  
  Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.
• Immunogen: Human epidermal keratin
• Localization: Cytoplasmic
• Marker: Epithelial Marker
• Specificity: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, which 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. AE-1/AE-3 is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It has been used to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has shown high sensitivity in the recognition of epithelial cells and carcinomas.
• Isotype: IgG1 Kappa/IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: KRT1
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • COMET
  • CyTOF-reported
  • Dual RNAscope ISH-IHC
  • Flow (Intracellular)
  • Flow Cytometry 1-2 ug/million cells
  • Immunocytochemistry/ Immunofluorescence 1-2 ug/ml
  • Immunohistochemistry
  • Immunohistochemistry-Frozen 0.5-1.0ug/ml
  • Immunohistochemistry-Paraffin 0.25-0.5 ug/ml
  • Multiplex Immunofluorescence
  • Single Cell Western 1:10
  • Western Blot 1-2 ug/ml
• Application Notes: Use in ICC/IF reported in scientific literature (PMID:34376789)
  Immunohistochemistry (Formalin-fixed): 0.25-0.5ug/ml for 30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
  Optimal dilution for a specific application should be determined.
  Western Blot: 1-2ug/ml for 2 hours at RT.
  The staining pattern of the pan cytokeratin antibody cocktail may be different than that of either antibody separately.
  This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, which 67 kDa (CK1) ; 64 kDa (CK3) ; 59 kDa (CK4) ; 58 kDa (CK5) ; 56 kDa (CK6) ; 52 kDa (CK8) ; 56.5 kDa (CK10) ; 50k Da (CK14) ; 50 kDa (CK15) ; 48 kDa (CK16) ; 40 kDa (CK19) . The pan cytokeratin cocktail does not react with keratin 18, which is also expressed in carcinomas. As such, negative staining with NBP2-29429 in of itself may not be sufficient evidence to rule out the possibility of a carcinoma (Ordonez, 2013) .
  For example, hepatocellular, adrenal cortical, clear cell renal and chromophobe renal cell carcinomas have been reported to be negative for the pan cytokeratin antibody. In this regard, the pan cytokeratin antibody can be used as part of a screening panel to more extensively define the tumor cell lineages.
  The pan cytokeratin antibody may cross-react with GFAP, leading to aberrant positive staining of glial tumors such as ependymoma, glioblastoma, or schwannoma (Ordonez, 2013) . Use in Immunohistochemistry reported in scientific literature (PMID: 29169625) . This Cytokeratin, pan Antibody (AE-1/AE-3) is validated for CyTOF from a verified customer review.

Reactivity Notes

Reptile reactivity reported in scientific literature (PMID: 11351328). Zebrafish reactivity reported in scientific literature (PMID: 30970016).

Packaging, Storage & Formulations

• Storage: Store at 4C.
• Buffer: 10 mM PBS with 0.05% BSA
• Preservative: 0.05% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: Protein A or G purified

Alternate Names for Cytokeratin, pan Antibody (AE-1/AE-3)

• AEI2
• CK1
• CK10
• CK13
• CK14
• CK15
• CK16
• CK-17
• CK-18
• CK19
• CK20
• CK-2e
• CK3
• CK4
• CK5
• CK6A
• CK8
• CK-9
• Cytokeratin, pan
• EHK
• EPPK
• K1
• K12
• KRT1
• KRT10
• KRT12
• KRT13
• KRT14
• KRT15
• KRT16
• KRT17
• KRT18
• KRT19
• KRT1A
• KRT2
• KRT20
• KRT3
• KRT4
• krt5
• KRT6A
• KRT8
• KRT9
• NEPPK
• panck

Background

Cytokeratins are a family of intermediate filamentous proteins that are expressed by epithelial cells (1,2). Cytokeratins range in size with a theoretic molecular weight varying from approximately 40 kDa to 68 kDa (2,3). The cytokeratin family consists of 20 polypeptides that are further divided into two main groups based on isoelectric point and molecular weight (1-3). The type I group are smaller, acidic polypeptides designated as cytokeratin 9 through cytokeratin 20 (CK9 - CK20) (1-4). Conversely, CK1 - CK8 belong to the type II group, classified as larger, basic or neutral polypeptides (1-4). Structurally, cytokeratins have homologous basic structure with other intermediate filaments; they possess a 300-315 amino acid (aa) central helical region that consists of four conserved domains (1A, 2A, 1B, and 2B) which are separated by linker domains (L1, L12, and L2) (1,5). Additionally, flanking this central region, both the amino- and carboxyl-terminal ends have a homologous subdomain (H), a variable domain (V), and charged end subdomains (E) (1). Furthermore, the central rod of one cytokeratin monomer binds with another monomer to form a coiled-coil dimer which subsequently binds another dimer to form a tertramer (3). Finally, many tetramers join together to ultimately form an intermediate filament of approximately 10nm in diameter (1-3, 5). Cytokeratins are expressed as pairs, typically with a type I and type II member; for example, CK10 pairs with CK1 (1,3).

Epithelial cells express multiple subtypes of cytokeratins which can be used to classify epithelial cell type or differentiation status, as well tumor progression or diagnosis (2). Cytokeratins are important for both stability and integrity of epithelial cells and function in intracellular signaling, from wound healing to apoptosis (1). Cytokeratins are useful immunohistochemistry tumor markers and antibodies to cytokeratins are a common pathological tool (1,3,6). Cytokeratin pan antibody is an antibody cocktail mixture that can detect multiple cytokeratins and reacts to multiple epithelial tissues (1,3,6). For example, AE-1/AE-3 is a commonly used specific pan cytokeratin that detects cytokeratins 1-8, 10, 14-16 and 19 (1,3,6).

Given the role of cytokeratins in the structural integrity of epithelial cells, mutations in cytokeratins have been shown to play a role in a variety of human diseases including epidermolysis bullosa simplex (EBS) (4,5). EBS is an autosomal dominant disorder that is caused by missense mutations in either CK5 or CK14 (5). Other known cytokeratin-related disorders include bullous ichthyosis, a skin disorder characterized by redness, blistering, and hyperkeratosis, and epidermolytic palmoplantar keratoderma (EPPK), which results in hyperkeratosis on the palms and soles of the body (7).

References

1. Awasthi, P., Thahriani, A., Bhattacharya, A., Awasthi, P., & Keratins, B. A. (2016). Keratins or cytokeratins: a review article. Journal of Advanced Medical and Dental Sciences Research. https://10.21276/jamdsr.2016.4.4.30

2. Southgate, J., Harnden, P., & Trejdosiewicz, L. K. (1999). Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histology and histopathology. https://doi.org/10.14670/HH-14.657

3. Belaldavar, C., Mane, D. R., Hallikerimath, S., Kale, A. D. (2016). Cytokeratins: Its role and expression profile in oral health and disease. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. https://doi.org/10.1016/j.ajoms.2015.08.001.

4. Linder S. (2007). Cytokeratin markers come of age. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. https://doi.org/10.1159/000107582

5. Jacob, J. T., Coulombe, P. A., Kwan, R., & Omary, M. B. (2018). Types I and II Keratin Intermediate Filaments. Cold Spring Harbor perspectives in biology. https://doi.org/10.1101/cshperspect.a018275

6. Ordonez N. G. (2013). Broad-spectrum immunohistochemical epithelial markers: a review. Human pathology. https://doi.org/10.1016/j.humpath.2012.11.016

7. McLean, W. H., & Moore, C. B. (2011). Keratin disorders: from gene to therapy. Human molecular genetics. https://doi.org/10.1093/hmg/ddr379

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Cytokeratin, pan Antibody (NBP2-29429)(78)

Publications using NBP2-29429

• van der Net, MC;Vliem, MJ;Kemp, LJS;Perez-Gonzalez, C;Haddad, TS;Strating, EA;Krotenberg-Garcia, A;Houtekamer, RM;Pannekoek, WJ;van den Anker, KB;Zwakenberg, S;Monster, JL;van der Horst, SEM;Snippert, HJG;Khalil, AA;van Rheenen, J;Suijkerbuijk, SJE;Kranenburg, O;Simmer, F;Nagtegaal, ID;Vignjevic, DM;Gloerich, M; Mechanosensitive calcium channels and integrins coordinate the reprogramming of colorectal cancer cells into a fetal-like state Cell reports 2025-09-22 [PMID: 40986425]
• Komar Z, Bavelaar M, Kageler E et al. Motion based ex vivo (MOTEX) culture of breast tumor slices sustains microenvironment composition Neoplasia (New York, N.Y.) 2025-10-01 [PMID: 40845489]
• Petit L, Belgacemi R, Mulette P et al. POU5F1 bridges Hedgehog signaling and epithelial remodeling in COPD Frontiers in Cell and Developmental Biology 2025-07-02 [PMID: 40673278]
• Ndiaye M, Garvey D, Chhabra G et al. PLK4 is a potential therapeutic target in nonmelanoma skin cancers: Evidence from molecular and in vivo studies. Photochemistry and photobiology 2025-06-16 [PMID: 40524317]
• Schmitz S, Gülden J, Niederreiter M et al. Strong Hsp90 alpha / beta Protein Expression in Advanced Primary CRC Indicates Short Survival and Predicts Response to the Hsp90 alpha / beta -Specific Inhibitor Pimitespib. Cells 2025-06-11 [PMID: 40498011]
• Ressler J, Plaschka M, Silmbrod R et al. Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial) Nature Cancer 2025-01-16 [PMID: 39820126]
• Yoon KA, Kim Y, Jung SY et Al. Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance Exp Mol Med 2024-11-01 [PMID: 39482530]
• Reinstein Z, Zhang Y, Ospina O et al. Pre-existing skin-resident CD8 and gamma δ T cell circuits mediate immune response in Merkel cell carcinoma and predict immunotherapy efficacy Cancer discovery 2025-03-29 [PMID: 39058036]
• Aaron G Baugh, Edgar Gonzalez, Valerie H Narumi, Jesse Kreger, Yingtong Liu, Christine Rafie, Sofi Castanon, Julie Jang, Luciane T Kagohara, Dimitra P Anastasiadou, James Leatherman, Todd Armstrong, Isaac Chan, George S Karagiannis, Elizabeth M Jaffee, Adam MacLean, Evanthia T Roussos Torres A new Neu-a syngeneic model of spontaneously metastatic HER2-positive breast cancer. Clinical & experimental metastasis 2024-05-08 [PMID: 38717519]
• Yuanli Zhen, Kai Liu, Lei Shi, Simran Shah, Qin Xu, Haley Ellis, Eranga R. Balasooriya, Johannes Kreuzer, Robert Morris, Albert S. Baldwin, Dejan Juric, Wilhelm Haas, Nabeel Bardeesy FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma Nature Communications 2024-05-07 [PMID: 38714664]
• Reed AD, Pensa S, Steif A et Al. A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast Nat Genet 2024-03-28 [PMID: 38548988]
• Altunbulakli C, Jimenez DG, Askmyr D et al. Targeted spatial proteomic analysis of CD8+ T- and myeloid cells in tonsillar cancer Frontiers in oncology 2023-11-17 [PMID: 38044986]
• Asemota S, Effah W, Young KL et al. Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype Cell reports 2023-11-17 [PMID: 37979170] (IHC, Human)
• Lauren E Colbert, Molly B El Alam, Rui Wang, Tatiana Karpinets, David Lo, Erica J Lynn, Timothy A Harris, Jacob H Elnaggar, Kyoko Yoshida-Court, Katarina Tomasic, Julianna K Bronk, Julie Sammouri, Ananta V Yanamandra, Adilene V Olvera, Lily G Carlin, Travis Sims, Andrea Y Delgado Medrano, Tatiana Cisneros Napravnik, Madison O'Hara, Daniel Lin, Chike O Abana, Hannah X Li, Patricia J Eifel, Anuja Jhingran, Melissa Joyner, Lilie Lin, Lois M Ramondetta, Andrew M Futreal, Kathleen M Schmeler, Geena Mathew, Stephanie Dorta-Estremera, Jianhua Zhang, Xiaogang Wu, Nadim J Ajami, Matthew Wong, Cullen Taniguchi, Joseph F Petrosino, K Jagannadha Sastry, Pablo C Okhuysen, Sara A Martinez, Lin Tan, Iqbal Mahmud, Philip L Lorenzi, Jennifer A Wargo, Ann H Klopp Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer cell 2023-11-16 [PMID: 37863066]
• Croft W, Pearce H, Margielewska-Davies S et al. Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma eLife 2023-06-23 [PMID: 37350578] (Block/Neutralize)
• Karabacak N, Zheng Y, Dubash T, et al. Single cell proteomics of tumor compartments identifies differential kinase activities defining sensitivity to mTOR-PI3-kinase inhibition bioRxiv 2021-01-10 (Mouse)
• Riedinger CJ, Esnakula A, Haight PJ et al. Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers Cancer 2023-09-26 [PMID: 37751191]
• Ying L, Zhang C, Reuben A et al. Immune-active tumor-adjacent tissues are associated with favorable prognosis in stage I lung squamous cell carcinoma iScience 2023-09-15 [PMID: 37694148]
• Wei CH, Huang L, Kreh B et al. A novel retinoic acid receptor-? agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment Sci Rep 2023-09-09 [PMID: 37689790]
• Gadwa J, Amann M, Bickett TE et al. Selective targeting of IL2R?? combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC Cell Reports Medicine 2023-08-15 [PMID: 37586327] (Flow Cytometry)
• Kim J, Kim S, Park SY et al. Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance Cancers (Basel) 2023-07-11 [PMID: 37509231] (Western Blot, Human)
• Jannone G, Bonaccorsi Riani E, de Magn�e C et al. Senescence and senotherapies in biliary atresia and biliary cirrhosis Aging (Albany NY) 2023-05-18 [PMID: 37204430]
• Roelofs P, Timmermans M, Stefanovska B et al. Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase Cells 2023-04-18 [PMID: 37190094]
• Carter JM, Chumsri S, Hinerfeld DA et al. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer Nature communications 2023-04-18 [PMID: 37072398] (IHC, Human)
• Ganguly D, Schmidt MO, Coleman M et al. Pleiotrophin drives a prometastatic immune niche in breast cancer The Journal of experimental medicine 2023-05-01 [PMID: 36828390] (IHC, Human)
• Estermann MA, Major AT, Smith CA DMRT1 regulation of TOX3 modulates expansion of the gonadal steroidogenic cell lineage in the chicken embryo Development (Cambridge, England) 2023-02-16 [PMID: 36794750] (IHC-Fr)
• Park S, Karalis JD, Hong C et al. ACTA2 expression predicts survival and is associated with response to immune checkpoint inhibitors in gastric cancer Clinical cancer research : an official journal of the American Association for Cancer Research 2022-12-12 [PMID: 36508166]
• Roelands J, van der Ploeg M, Ijsselsteijn ME Et al. Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis Gut 2022-11-28 [PMID: 36442992] (IHC-P, Human)
  
  Details:
  Citation using the Alexa Fluor 488 version of this antibody.
• Zhang Q, Abdo R, Iosef C et al. The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis Nature Communications 2022-10-10 [PMID: 36216799]
• Hur JY, Ku BM, Park S et al. Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma PloS one 2022-10-06 [PMID: 36201479] (IHC-P, Human)
  
  Details:
  Dilution used in IHC 1:500
• Yerly L, Pich-Bavastro C, Di Domizio J Et al. Integrated multi-omics reveals cellular and molecular interactions governing the invasive niche of basal cell carcinoma Nat Commun 2022-08-19 [PMID: 35986012] (IHC-P, Human)
  
  Details:
  Citation using the Azide and BSA Free version of this antibody.
• Forsythe SD, Erali RA, Laney P et al. Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research Scientific reports 2022-08-16 [PMID: 35974123] (IHC-P, Human)
• Hwang WL, Jagadeesh KA, Guo JA Et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment Nat Genet 2022-07-28 [PMID: 35902743] (IHC-P, Human)
  
  Details:
  Citation using the Alexa Fluor 532 version of this antibody.
• Schmitd LB, Perez-Pacheco C, Bellile EL et al. Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer Clinical Cancer Research 2022-08-15 [PMID: 35819260]
• Ozturk H, Cingoz H, Tufan T Et al. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer Dev Cell 2022-05-04 [PMID: 35508175]
  
  Details:
  Citation using the Azide and BSA Free version of this antibody.
• Kim HD, Kim SY, Kim J et al. Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment Scientific reports 2022-01-31 [PMID: 35102212] (Western Blot, Human)
• Dance YW, Meshulam T, Seibel AJ Et al. Adipose Stroma Accelerates the Invasion and Escape of Human Breast Cancer Cells from an Engineered Microtumor Cell Mol Bioeng 2022-01-31 [PMID: 35096184]
  
  Details:
  Citation using the Azide and BSA Free version of this antibody.
• Minjung Seo, Yeji Kim, Byong Duk Ye, Sang Hyoung Park, Seog-Young Kim, Jin Hwa Jung, Sung Wook Hwang, Sun Young Chae, Dong Yun Lee, Sang Ju Lee, Seung Jun Oh, Jihun Kim, Ji Young Kim, Sae Jung Na, Misung Kim, Sang-Yeob Kim, Norman Koglin, Andrew W Stephens, Mi-Na Kweon, Dae Hyuk Moon PET Imaging of System x C - in Immune Cells for Assessment of Disease Activity in Mice and Patients with Inflammatory Bowel Disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2022-10-05 [PMID: 35086893]
• Yoshida Y, Ding X, Iwatsuki K Et al. Detection of Lung Cancer Cells in Solutions Using a Terahertz Chemical Microscope Sensors (Basel, Switzerland) 2021-11-17 [PMID: 34833707] (Human)
• Khan M, Yoo SJ, Clijsters M et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb Cell 2021-11-01 [PMID: 34798069] (IHC)
• Yamamoto H, Elbadawy M, Fujisaka K et al. Evaluation of the Safety and Feasibility of Apheresis in Dogs: For Application in Metastatic Cancer Research Animals 2021-09-23 [PMID: 34679792] (ICC/IF, Human)
• Cho JW, Park S, Kim G Et al. Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer Nature communications 2021-10-18 [PMID: 34663810] (IHC-P, Human)
• Estermann MA, Mariette MM, Moreau JLM et al. PAX2 (+) Mesenchymal Origin of Gonadal Supporting Cells Is Conserved in Birds Frontiers in Cell and Developmental Biology 2021-08-27 [PMID: 34513849] (Western Blot, Human)
• Estermann MA, Hirst CE, Major AT, Smith CA The homeobox gene TGIF1 is required for chicken ovarian cortical development and generation of the juxtacortical medulla Development (Cambridge, England) 2021-08-15 [PMID: 34387307] (IF/IHC, Chicken)
• Shiokawa M, Miura R, Okubo A Et al. Bovine endometrium-derived cultured cells are suitable for lipofection Scientific reports 2021-08-10 [PMID: 34376789] (ICC/IF, Bovine)
• Hamdan F, YlOsmAki E, Chiaro J et al. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids J Immunother Cancer 2021-11-01 [PMID: 34362830] (ICC/IF, Human)
• Zhou X, Chen Z, Pei L, Sun J. MicroRNA miR-106a-5p targets forkhead box transcription factor FOXC1 to suppress the cell proliferation, migration, and invasion of ectopic endometrial stromal cells via the PI3K/Akt/mTOR signaling pathway Bioengineered 2021-06-04 [PMID: 34082653] (Western Blot, Human)
• Oppel, F, Ki, D H Et al. suz12 inactivation in p53 and nf1 deficient zebrafish accelerates the onset of MPNSTs and expands the spectrum of tumor types to include adenocarcinoma, leukemia, and soft tissue sarcoma. Dis Model Mech 2020-01-01 [PMID: 34005093]
• YAMAGIWA Y, MASATSUGU M, TAHARA H et al. Orbital malignant schwannoma and embryonal rhabdomyosarcoma in rats caused by leakage of locally injected nickel subsulfide to the orbit J Toxicol Pathol 2021-05-12 [PMID: 33976471]
• Brady L, Kriner M, Coleman I et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling Nature communications 2021-03-03 [PMID: 33658518] (IHC-P, Human)
• Kim HD, Jeong S, Park S et al. Implication of CD69+ CD103+ tissue-resident-like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma Liver international : official journal of the International Association for the Study of the Liver 2021-02-06 [PMID: 33548061]
• Jones I, Novikova LN, Wiberg M et Al. Human Embryonic Stem Cell-derived Neural Crest Cells Promote Sprouting and Motor Recovery Following Spinal Cord Injury in Adult Rats Cell Transplant 2021-01-31 [PMID: 33522309]
• Abd Raboh N, Mady O, Hakim S Evaluation of the Potential Prognostic Value of Tumor Budding in Laryngeal Carcinoma by Conventional and Immunohistochemical Staining Analytical Cellular Pathology 2020-11-13 [PMID: 33274177]
• Kim HD, Kim JH, Ryu YM et al. Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer Cancer Res Treat 2020-08-31 [PMID: 32878426] (IF/IHC, Human)
• Oppel F, Ki DH, Zimmermann MW et al. suz12 inactivation in p53 and nf1 deficient zebrafish accelerates the onset of MPNSTs and expands the spectrum of tumor types to include adenocarcinoma, leukemia, and soft tissue sarcoma Dis Model Mech 2020-07-10 [PMID: 32651197] (ICC/IF, Zebrafish)
• Liu Z, Murphy SF, Huang J et al. A novel immunocompetent model of metastatic prostate cancer-induced bone pain Prostate 2020-07-01 [PMID: 32407603]
• Estermann MA, Williams S, Hirst CE et al. Insights into Gonadal Sex Differentiation Provided by Single-Cell Transcriptomics in the Chicken Embryo Cell Rep 2020-04-07 [PMID: 32268081] (IHC-Fr, Chicken)
• Fukushima K, Satoh T, Sugihara F et Al. Dysregulated Expression of the Nuclear Exosome Targeting Complex Component Rbm7 in Nonhematopoietic Cells Licenses the Development of Fibrosis Immunity. [PMID: 32187520]
• Dey P, Li J, Zhang J et al. Oncogenic Kras driven metabolic reprogramming in pancreas cancer cells utilizes cytokines from the tumor microenvironment Cancer Discov 2020-02-11 [PMID: 32046984] (IHC-P, Human)
• Roly ZY, Major AT, Fulcher A, et al. Adhesion G-protein coupled receptor, GPR56, is required for MUllerian duct development in the chick J. Endocrinol. 2019-12-01 [PMID: 31829965] (IF/IHC, Chicken)
• Oppel F, Tao T, Shi H et al. Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies. PLoS Genet. 2019-04-10 [PMID: 30970016] (IHC-P, Zebrafish)
  
  Details:
  Citation using the Azide and BSA Free form of this antibody.
• Wan J, Block S, Scribano CM et al. Mad1 destabilizes p53 by preventing PML from sequestering MDM2 Nature communications 2019-04-04 [PMID: 30948704] (IHC-P, Human)
• Sato K, Kurita T et al. Distribution of label-retaining cells and their properties in the vocal fold mucosa. Laryngoscope Investig Otolaryngol 2019-01-02 [PMID: 30828622] (IF/IHC, Rat)
• Jensen T, Wanczyk H, Sharma I et al. Polyurethane scaffolds seeded with autologous cells can regenerate long esophageal gaps: An esophageal atresia treatment model. J Pediatr Surg. 2018-10-22 [PMID: 30429066] (ICC/IF)
  
  Details:
  Citation using the Azide and BSA Free form of this antibody.
• Diaz R J, Luck A et al. Characterization of a Clival Chordoma Xenograft Model Reveals Tumor Genomic Instability. Am J Pathol 2018-01-12 [PMID: 30248342] (IF/IHC, Mouse)
• Ijsselsteijn ME, Brouwer TP, Abdulrahman Z et al. Cancer immunophenotyping by 7 colour multispectral imaging without tyramide signal amplification J Pathol Clin Res. 2018-01-01 [PMID: 30191683] (ICC/IF, Human)
  
  Details:
  Citation using the Alexa Fluor 647 form of this antibody.
• Cho CJ, Kang HJ, Ryu YM et al. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. Gastric Cancer 2018-04-07 [PMID: 29627937] (Human)
• Banco B, Ferrari R, Stefanello D et al. Ovarian Embryonal Carcinoma in a Dog J. Comp. Pathol. 2017-11-01 [PMID: 29169625] (IF/IHC, Canine)
• Colinot DL, Garbuz T, Bosland MC et al. The common parasite Toxoplasma gondii induces prostatic inflammation and microglandular hyperplasia in a mouse model. Prostate 2017-05-12 [PMID: 28497488] (Western Blot, Human)
• Ordonez NG. Broad-spectrum immunohistochemical epithelial markers: a review. Hum Pathol. 2013-07-01 [PMID: 23427873] (IHC-P)
  
  Details:
  IHC (P): Table 1
• Niikura H, Okamoto S, Yoshinaga K et al. Detection of micrometastases in the sentinel lymph nodes of patients with endometrial cancer. Gynecol Oncol. 2007-06-01 [PMID: 17442382] (IHC-P)
  
  Details:
  IHC (paraffin): Fig 1 & Table 2 (lymph nodes from endometrial cancer and other patients).
• Berg A, Berner A, Lilleby W et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer. 2007-04-15 [PMID: 17230512] (ICC/IF)
  
  Details:
  ICC: Figs 1-3, Tables II-IV (bone marrow cytospins from prostate cancer patients).
• Azumi M, Saga Y, Hashimoto H et al. [Histological investigation of prostate cancer treated with hormonal agents]. Hinyokika Kiyo. 2006-10-01 [PMID: 17131867]
  
  Details:
  Prostate specimens, see publication for details.
• Wiedswang G, Borgen E, Karesen R et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res. 2004-08-15 [PMID: 15328170]
  
  Details:
  ICC: Tables 1-4, Figs 1-3 (bone marrow cytospins). The Cytokeratin AE1/AE3 antibody was used to identify isolated tumor cells in bone marrow.
• Alexander-Sefre F, Singh N, Ayhan A et al. Assessment of the depth of myometrial invasion in stage I endometrioid endometrial cancer using pancytokeratin immunohistochemistry. Int J Gynecol Cancer. 2004-07-01 [PMID: 15304163] (IHC-P)
  
  Details:
  IHC (paraffin): Figs 2-5, Table I (endometrial cancer).
• Krishnamurthy S, Sneige N, Ordonez NG et al. Characterization of foam cells in nipple aspirate fluid. Diagn Cytopathol. 2002-11-01 [PMID: 12411988] (ICC)
  
  Details:
  ICC: Fig 2B (nipple aspirate fluid). The Cytokeratin AE1/AE3 antibody helped demonstrate, through negative staining, that the foam cells were not of epithelial origin.
• Alibardi L, Maurizii M, Taddei C. Immunocytochemical and electrophoretic distribution of cytokeratins in the resting stage epidermis of the lizard Podarcis sicula. J Exp Zool. 2001-06-01 [PMID: 11351328] (WB, ICC/IF, Lizards)
  
  Details:
  Adult lizards: IF/ICC (Fig. 2), IHC [(acrylic resin) Fig 3], WB (Fig 4)
• Woodcock-Mitchell J, Eichner R, Nelson WG et al. Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol. 1982-11-01 [PMID: 6183275] (WB, Human)
  
  Details:
  Hydridoma development of the AE1 and AE3 antibody clones, first clone specific publication: IF: Fig 1 (primary human epidermal cell cultures) WB: Fig 2 (human epidermal keratins, cytoskeletal proteins from human abdominal epidermis, human fibroblasts); Fig 3 (karains separated by 2D PAGE); Fig 7 (human heel epidermis) IHC (F): Figs 4-6 (human skin) Note: The specificity of the antibody clones were validated by WB using isolated keratins separated by 2D SDS-PAGE (Fig 2).

Review for Cytokeratin, pan Antibody (NBP2-29429) (1)

Average Rating: 4

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Toni johanson CyTOF Human 03/31/2021

Summary

• Application: CyTOF
• Sample Tested: fibroblasts
• Species: Human
• Lot: MSM2-371P201203

Comments

• Comments: ***Bio-Techne Response: This review was submitted through the legacy Novus Innovators Program, reflecting a new species or application tested on a primary antibody.***

FAQs for Cytokeratin, pan Antibody (NBP2-29429). (Showing 1 - 1 of 1 FAQs).

1. Could you tell us recommended antigen retrieval method for this antibody?-EndFragment-->
   • Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes. Optimal dilution of antibody for IHC should be determined by the user. 

Bioinformatics

• Gene Symbol: KRT1
• Uniprot:
  • Q01546(Human)
  • Q7Z794(Human)